NCT04873141View on ClinicalTrials.gov

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

June 22, 2020

Study Completion Date

June 22, 2020

Conditions
Cytokine Release SyndromeCovid-19 Pneumonia
Interventions
DRUG

Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)

Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).

Trial Locations (1)

44000

Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad

All Listed Sponsors
lead

Shaheed Zulfiqar Ali Bhutto Medical University

OTHER

NCT04873141 - Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia | Biotech Hunter | Biotech Hunter